These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23315223)

  • 1. [Statin-induced adverse effects -- facts and genes].
    Harangi M; Zsíros N; Juhász L; Paragh G
    Orv Hetil; 2013 Jan; 154(3):83-92. PubMed ID: 23315223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of statin-intolerant patient.
    Arca M; Pigna G; Favoccia C
    Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin induced myopathy.
    Frank RE
    J Insur Med; 2009; 41(2):132-5. PubMed ID: 19845216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle aches and pains from statin use. Discomfort usually resolves with a lower dose or a different statin.
    Harv Heart Lett; 2012 Oct; 23(2):5. PubMed ID: 23437465
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin-induced myopathy: a review and update.
    Abd TT; Jacobson TA
    Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.
    Harris LJ; Thapa R; Brown M; Pabbathi S; Childress RD; Heimberg M; Braden R; Elam MB
    J Clin Lipidol; 2011; 5(4):299-307. PubMed ID: 21784376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
    Laaksonen R; Katajamaa M; Päivä H; Sysi-Aho M; Saarinen L; Junni P; Lütjohann D; Smet J; Van Coster R; Seppänen-Laakso T; Lehtimäki T; Soini J; Oresic M
    PLoS One; 2006 Dec; 1(1):e97. PubMed ID: 17183729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
    Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
    Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity.
    Gillett RC; Norrell A
    Am Fam Physician; 2011 Mar; 83(6):711-6. PubMed ID: 21404982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statin therapy and muscle disorders].
    Abel T; Fehér J
    Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin myopathy: a review of recent progress.
    Mammen AL; Amato AA
    Curr Opin Rheumatol; 2010 Nov; 22(6):644-50. PubMed ID: 20827205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group.
    Stock J
    Atherosclerosis; 2015 Sep; 242(1):346-50. PubMed ID: 26253793
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Muscle problems due to statins: underestimated].
    Janssen SP; Smulders YM; Gerdes VE; Visseren FL
    Ned Tijdschr Geneeskd; 2010; 154():A1684. PubMed ID: 21435278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic determinants of statin intolerance.
    Oh J; Ban MR; Miskie BA; Pollex RL; Hegele RA
    Lipids Health Dis; 2007 Mar; 6():7. PubMed ID: 17376224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin myopathy: over-rated and under-treated?
    Maghsoodi N; Wierzbicki AS
    Curr Opin Cardiol; 2016 Jul; 31(4):417-25. PubMed ID: 27258372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing statin myopathy.
    Venero CV; Thompson PD
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):121-36. PubMed ID: 19217515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.
    Chien SC; Chen PS; Huang YH; Tang SC; Li YH; Yeh HI
    J Formos Med Assoc; 2019 Oct; 118(10):1385-1392. PubMed ID: 30584005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming toxicity and side-effects of lipid-lowering therapies.
    Wilkinson MJ; Laffin LJ; Davidson MH
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):439-52. PubMed ID: 24840269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin myotoxicity: a review of genetic susceptibility factors.
    Needham M; Mastaglia FL
    Neuromuscul Disord; 2014 Jan; 24(1):4-15. PubMed ID: 24176465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.